Clinical Trial Update: Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety and potential efficacy of combining ceritinib with nivolumab in patients with ALK-positive non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• OPDIVO (nivolumab)
• Zykadia (ceritinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: ALK-positive NSCLC | Phase 1 | Status: ACTIVE_NOT_RECRUITING